Ultimovacs - Patient expansion in Phase I TENDU
Ultimovacs has announced the extension of its Phase I TENDU trial in prostate cancer following positive interim safety results. The study has so far enrolled nine patients and, following review by the trial’s drug safety monitoring board, no safety concerns in any of the three dose cohorts were identified. The trial will now recruit up to three additional patients to be treated at a highest-dose level (960 mcg). The TENDU study is investigating the use of the company’s proprietary Tetanus-Epitope Targeting (TET) cancer vaccine technology in treating prostate cancer patients who have relapsed after radical prostatectomy. The primary goal is to assess the safety of the TET-derived vaccine, therefore, in our view, these positive results are highly encouraging. With much of Ultimovacs’ recent activity focused on the development of its lead cancer vaccine candidate (UV1), we believe the company’s TET vaccine programme could provide future value. We continue to value Ultimovacs at NOK6.90bn, or NOK202/share.Ultimovacs ASA Formerly known as Ultimovacs AS. Ultimovacs ASA, formerly Ultimovacs AS, is a Norway-based pharmaceutical company developing immunotherapies against cancer. The Company's lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs which require an ongoing T cell response for their mode of action. The Company is performing a broad clinical development program with clinical trials in Europe and the USA.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.